[1] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[2] SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.
[3] DONG H,HU J,ZOU K,et al.Activation of LncRNA TINCR by H3K27 acetylation promotes trastuzumab resistance and epithelial-mesenchymal transition by targeting microRNA-125b in breast cancer[J].Mol Cancer,2019,18(1):3.
[4] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志,2021,31(10):954-1040.
[5] MITTAL D,GUBIN M M,SCHREIBER R D,et al.New insights into cancer immunoediting and its three component phases-elimination,equilibrium and escape[J].Curr Opin Immunol,2014,27:16-25.
[6] GAJEWSKI T F,SCHREIBER H,FU Y X.Innate and adaptive immune cells in the tumor microenvironment[J].Nat Immunol,2013,14(10):1014-1022.
[7] YAMAGUCHI R,TANAKA M,YANO A,et al.Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer[J].Hum Pathol,2012,43(10):1688-1694.
[8] LI X B,KRISHNAMURTI U,BHATTARAI S,et al.Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer[J].Am J Clin Pathol,2016,145(6):871-878.
[9] 杨云松,江一舟,胡欣,等.乳腺肿瘤微环境靶向治疗的研究进展[J].中国癌症杂志,2019,29(12):977-984.
[10] STANTON S E,ADAMS S,DISIS M L.Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes:a systematic review[J].JAMA Oncol,2016,2(10):1354-1360.
[11] HONG J,RUI W,FEI X,et al.Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer[J].Cancer Med,2021,10(22):7921-7933.
[12] COULIE P G,VAN DEN EYNDE B J,VAN DER BRUGGEN P,et al.Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy[J].Nat Rev Cancer,2014,14(2):135-146.
[13] SALGADO R,DENKERT C,DEMARIA S,et al.The evaluation of tumor-infiltrating lymphocytes(TILs) in breast cancer:recommendations by an International TILs Working Group 2014[J].Ann Oncol,2015,26(2):259-271.
[14] SWISHER S K,WU Y,CASTANEDA C A,et al.Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes(TILs) in breast cancer using methodology proposed by the international TILs working group[J].Ann Surg Oncol,2016,23(7):2242-2248.
[15] CHA Y J,AHN S G,BAE S J,et al.Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens:a retrospective analysis[J].Breast Cancer Res Treat,2018,171(2):295-302.
[16] HENDRY S,SALGADO R,GEVAERT T,et al.Assessing tumor-infiltrating lymphocytes in solid tumors:a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group:Part 1:assessing the host immune response,TILs in invasive breast carcinoma and ductal carcinoma in situ,metastatic tumor deposits and areas for further research[J].Adv Anat Pathol,2017,24(5):235-251.
[17] STACK E C,FOUKAS P G,LEE P P.Multiplexed tissue biomarker imaging[J].J Immunother Cancer,2016,4:9.
[18] YOUNG Y K,BOLT A M,AHN R,et al.Analyzing the tumor microenvironment by flow cytometry[J].Methods Mol Biol,2016,1458:95-110.
[19] GENTLES A J,NEWMAN A M,LIU C L,et al.The prognostic landscape of genes and infiltrating immune cells across human cancers[J].Nat Med,2015,21(8):938-945.
[20] BIAN T,WU Z,LIN Q,et al.Evaluating tumor-infiltrating lymphocytes in breast cancer using preoperative MRI-based radiomics[J].J Magn Reson Imaging,2022,55(3):772-784.
[21] TANG W J,KONG Q C,CHENG Z X,et al.Performance of radiomics models for tumour-infiltrating lymphocyte(TIL) prediction in breast cancer:the role of the dynamic contrast-enhanced(DCE) MRI phase[J].Eur Radiol,2022,32(2):864-875.
[22] XU N,ZHOU J,HE X,et al.Radiomics model for evaluating the level of tumor-infiltrating lymphocytes in breast cancer based on dynamic contrast-enhanced MRI[J].Clin Breast Cancer,2021,21(5):440-449.
[23] ZHENG S,LI L,CHEN M,et al.Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer:a retrospective cohort study at FUSCC[J].Breast,2022,63:177-186.
[24] DE AZAMBUJA E,HOLMES A P,PICCART-GEBHART M,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):survival outcomes of a randomised,open-label,multicentre,phase 3 trial and their association with pathological complete response[J].Lancet Oncol,2014,15(10):1137-1146.
[25] INGOLD H B,UNTCH M,DENKERT C,et al.Tumor-infiltrating lymphocytes:a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer[J].Clin Cancer Res,2016,22(23):5747-5754.
[26] SALGADO R,DENKERT C,CAMPBELL C,et al.Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab:a secondary analysis of the NeoALTTO trial[J].JAMA Oncol,2015,1(4):448-454.
[27] HAMY A S,PIERGA J Y,SABAILA A,et al.Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer[J].Ann Oncol,2017,28(9):2233-2240.
[28] DE ANGELIS C,NAGI C,HOYT C C,et al.Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy[J].Clin Cancer Res,2020,26(3):738-745.
[29] CORTAZAR P,ZHANG L,UNTCH M,et al.Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis[J].Lancet,2014,384(9938):164-172.
[30] DENKERT C,VON MINCKWITZ G,DARB-ESFAHANI S,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:a pooled analysis of 3771 patients treated with neoadjuvant therapy[J].Lancet Oncol,2018,19(1):40-50.
[31] LUNDGREN C,BENDAHL P O,EKHOLM M,et al.Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer:data from a randomised trial with long-term follow-up[J].Breast Cancer Res,2020,22(1):140.
[32] HAMY A S,BONSANG-KITZIS H,DE CROZE D,et al.Interaction between molecular subtypes and stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy[J].Clin Cancer Res,2019,25(22):6731-6741.
[33] GAO Z H,LI C X,LIU M,et al.Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes:a meta-analysis[J].BMC Cancer,2020,20(1):1150.
[34] CHAE H,YOO C,YOON J A,et al.FcrR3A-158 polymorphism and stromal tumor-infiltrating lymphocytes and survival among patients with metastatic HER2-positive breast cancer receiving trastuzumab-based treatment[J].J Breast Cancer,2018,21(1):45-50.
[35] BADVE S S,PENAULT-LLORCA F,REIS-FILHO J S,et al.Determining PD-L1 status in patients with triple-negative breast cancer:lessons learned from IMpassion130[J].J Natl Cancer Inst,2021,114(5):664-675.
[36] ZHAO J,MEISEL J,GUO Y,et al.Evaluation of PD-L1,tumor-infiltrating lymphocytes,and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies[J].Breast Cancer Res Treat,2020,183(3):599-606.
[37] BIANCHINI G,GIANNI L.The immune system and response to HER2-targeted treatment in breast cancer[J].Lancet Oncol,2014,15(2):e58-e68.
[38] LOI S,GIOBBIE-HURDER A,GOMBOS A,et al.Pembrolizumab plus trastuzumab in trastuzumab-resistant,advanced,HER2-positive breast cancer(PANACEA):a single-arm,multicentre,phase 1b-2 trial[J].Lancet Oncol,2019,20(3):371-382.
[39] KODUMUDI K N,RAMAMOORTHI G,SNYDER C,et al.Sequential anti-PD1 therapy following dendritic cell vaccination improves survival in a HER2 mammary carcinoma model and identifies a critical role for CD4 T cells in mediating the response[J].Front Immunol,2019,10:1939. |
